6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group

Item Type:	Article
Title:	6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group
Creators Name:	Buechner, T. and Hiddemann, W. and Berdel, W.E. and Woermann, B. and Schoch, C. and Fonatsch, C. and Loeffler, H. and Haferlach, T. and Ludwig, W.D. and Maschmeyer, G. and Staib, P. and Aul, C. and Grueneisen, A. and Lengfelder, E. and Frickhofen, N. and Kern, W. and Serve, H.L. and Mesters, R.M. and Sauerland, M.C. and Heinecke, A.
Source:	Journal of Clinical Oncology
ISSN:	0732-183X
Volume:	21
Page Range:	4496-4504
Date:	15 December 2003
Official Publication:	https://doi.org/10.1200/JCO.2003.02.133
PubMed:	View item in PubMed

Repository Staff Only: item control page